One new strategy to enhance the breadth of type-specific neutralizing antibody responses after infection or vaccination centers around the design of chimeric immunogens encoding admixtures of EDI, EDII, and EDIII from two or more DENV serotypes [164,190,191]. The gene discussed is TNRC6A; the disease is infection.